Advances in RPGR gene therapy for X‑linked retinitis pigmentosa: From preclinical insights to clinical application (Review)

Wang Y, Liu S, Zhai Y, Liu Y, Wan X, Wang W, Wang F and Sun X: Identification of a novel RPGR mutation associated with X-linked cone-rod dystrophy in a Chinese family. BMC Ophthalmol. 21:4012021. View Article : Google Scholar : PubMed/NCBI

Liu W, Liu S, Li P and Yao K: Retinitis Pigmentosa: Progress in molecular pathology and biotherapeutical strategies. Int J Mol Sci. 23:48832022. View Article : Google Scholar : PubMed/NCBI

Benson MD, Mukherjee S, Agather AR, Blain D, Cunningham D, Mays R, Sun X, Li T, Hufnagel RB, Brooks BP, et al: RPGR: Deep phenotyping and genetic characterization with findings specific to the 3'-end of ORF15. Invest Ophthalmol Vis Sci. 64:192023. View Article : Google Scholar : PubMed/NCBI

Qin H, Zhang W, Zhang S, Feng Y, Xu W, Qi J, Zhang Q, Xu C, Liu S, Zhang J, et al: Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas. J Exp Med. 220:e202207762023. View Article : Google Scholar : PubMed/NCBI

Liu YS, Pan JQ, Wan JF, Ren CY, Xu ZH, Pan XB, Gao RN, Liu SQ, Zhang JL, Yao QH, et al: A novel missense mutation of RPGR identified from retinitis pigmentosa affects splicing of the ORF15 region and causes loss of transcript heterogeneity. Biochem Biophys Res Commun. 531:172–179. 2020. View Article : Google Scholar : PubMed/NCBI

Murga-Zamalloa C, Swaroop A and Khanna H: Multiprotein complexes of Retinitis Pigmentosa GTPase regulator (RPGR), a ciliary protein mutated in X-linked Retinitis Pigmentosa (XLRP). Adv Exp Med Biol. 664:105–114. 2010. View Article : Google Scholar : PubMed/NCBI

Moreno-Leon L, West EL, O'Hara-Wright M, Li L, Nair R, He J, Anand M, Sahu B, Chavali VRM, Smith AJ, et al: RPGR isoform imbalance causes ciliary defects due to exon ORF15 mutations in X-linked retinitis pigmentosa (XLRP). Hum Mol Genet. 29:3706–3716. 2021. View Article : Google Scholar :

Sladen PE, Naeem A, Adefila-Ideozu T, Vermeule T, Busson SL, Michaelides M, Naylor S, Forbes A, Lane A and Georgiadis A: AAV-RPGR gene therapy rescues opsin mislocalisation in a human retinal organoid model of RPGR-Associated X-linked retinitis pigmentosa. Int J Mol Sci. 25:18392024. View Article : Google Scholar : PubMed/NCBI

Awadh Hashem S, Georgiou M, Ali RR and Michaelides M: RPGR-Related Retinopathy: Clinical features, molecular genetics, and gene replacement therapy. Cold Spring Harb Perspect Med. 13:a0412802023. View Article : Google Scholar : PubMed/NCBI

Cehajic Kapetanovic J, McClements ME, Martinez-Fernandez de la Camara C and MacLaren RE: Molecular strategies for RPGR gene therapy. Genes (Basel). 10:6742019. View Article : Google Scholar : PubMed/NCBI

Karuntu JS, Almushattat H, Nguyen XT, Plomp AS, Wanders RJA, Hoyng CB, van Schooneveld MJ, Schalij-Delfos NE, Brands MM, Leroy BP, et al: Syndromic Retinitis Pigmentosa. Prog Retin Eye Res. 107:1013242025. View Article : Google Scholar

Hartong DT, Berson EL and Dryja TP: Retinitis pigmentosa. Lancet. 368:1795–1809. 2006. View Article : Google Scholar : PubMed/NCBI

Rivas MA and Vecino E: Animal models and different therapies for treatment of retinitis pigmentosa. Histol Histopathol. 24:1295–1322. 2009.PubMed/NCBI

Liu Y, Zong X, Cao W, Zhang W, Zhang N and Yang N: Gene therapy for retinitis pigmentosa: Current challenges and new progress. Biomolecules. 14:9032024. View Article : Google Scholar : PubMed/NCBI

Napoli D, Di Marco B, Salamone G, Orsini N, Mazziotti R and Strettoi E: Keeping the lights on: A new role for an old drug to support cone survival in Retinitis Pigmentosa. Prog Retin Eye Res. 109:1014032025. View Article : Google Scholar : PubMed/NCBI

Ghanawi H and Koch SF: The versatile roles of retinal pigment epithelium in the pathophysiology of retinitis pigmentosa. Prog Retin Eye Res. 108:1013902025. View Article : Google Scholar : PubMed/NCBI

Thompson DA, Khan NW, Othman MI, Chang B, Jia L, Grahek G, Wu Z, Hiriyanna S, Nellissery J, Li T, et al: Rd9 is a naturally occurring mouse model of a common form of retinitis pigmentosa caused by mutations in RPGR-ORF15. PLoS One. 7:e358652012. View Article : Google Scholar : PubMed/NCBI

Birch DG, Cheetham JK, Daiger SP, Hoyng C, Kay C, MacDonald IM, Pennesi ME and Sullivan LS: Overcoming the challenges to clinical development of X-Linked retinitis pigmentosa therapies: Proceedings of an expert panel. Transl Vis Sci Technol. 12:52023. View Article : Google Scholar : PubMed/NCBI

Chivers M, Li N, Pan F, Wieffer H, Slowik R and Leartsakulpanitch J: The Burden of X-Linked retinitis pigmentosa on patients and society: A narrative literature review. Clinicoecon Outcomes Res. 13:565–572. 2021. View Article : Google Scholar : PubMed/NCBI

Jiang J, Wu X, Shen D, Dong L, Jiao X, Hejtmancik JF and Li N: Analysis of RP2 and RPGR mutations in five X-linked Chinese families with retinitis pigmentosa. Sci Rep. 7:444652017. View Article : Google Scholar : PubMed/NCBI

Li L, Khan N, Hurd T, Ghosh AK, Cheng C, Molday R, Heckenlively JR, Swaroop A and Khanna H: Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration. Invest Ophthalmol Vis Sci. 54:4503–4511. 2013. View Article : Google Scholar : PubMed/NCBI

Fischer MD, McClements ME, Martinez-Fernandez de la Cama ra C, Bellingrath JS, Dauletbekov D, Ramsden SC, Hickey DG, Barnard AR and MacLaren RE: Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in two mouse models of X-Linked Retinitis pigmentosa. Mol Ther. 25:1854–1865. 2017. View Article : Google Scholar : PubMed/NCBI

Ebenezer ND, Michaelides M, Jenkins SA, Audo I, Webster AR, Cheetham ME, Stockman A, Maher ER, Ainsworth JR, Yates JR, et al: Identification of novel RPGR ORF15 mutations in X-linked progressive cone-rod dystrophy (XLCORD) families. Invest Ophthalmol Vis Sci. 46:1891–1898. 2005. View Article : Google Scholar : PubMed/NCBI

Talib M, van Schooneveld MJ, Thiadens AA, Fiocco M, Wijnholds J, Florijn RJ, Schalij-Delfos NE, van Genderen MM, Putter H, Cremers FPM, et al: Clinical and genetic characteristics of male patients with RPGR-associated retinal dystrophies: A Long-term follow-up study. Retina. 39:1186–1199. 2019. View Article : Google Scholar

MacLaren RE, Duncan JL, Fischer MD, Lam BL, Meunier I, Pennesi ME, Sankila EK, Gow JA, Li J and Tsang SF: XOLARIS: A 24-Month, prospective, natural history study of 201 participants with retinitis pigmentosa GTPase Regulator-associated X-linked retinitis pigmentosa. Ophthalmol Sci. 5:1005952025. View Article : Google Scholar

Birtel J, Gliem M, Mangold E, Müller PL, Holz FG, Neuhaus C, Lenzner S, Zahnleiter D, Betz C, Eisenberger T, et al: Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa. PLoS One. 13:e02079582018. View Article : Google Scholar : PubMed/NCBI

Gill JS, Georgiou M, Kalitzeos A, Moore AT and Michaelides M: Progressive cone and cone-rod dystrophies: Clinical features, molecular genetics and prospects for therapy. Br J Ophthalmol. 103:711–720. 2019. View Article : Google Scholar : PubMed/NCBI

Lam BL, Pennesi ME, Kay CN, Panda S, Gow JA, Zhao G and MacLaren RE: Assessment of visual function with cotoretigene toliparvovec in X-linked retinitis pigmentosa in the randomized XIRIUS phase 2/3 study. Ophthalmology. 131:1083–1093. 2024. View Article : Google Scholar : PubMed/NCBI

Nuzbrokh Y, Ragi SD and Tsang SH: Gene therapy for inherited retinal diseases. Ann Transl Med. 9:12782021. View Article : Google Scholar : PubMed/NCBI

De Silva SR, Chan HW, Agarwal A, Webster AR, Michaelides M and Mahroo OA: Visual acuity by decade in 139 males with RPGR-Associated retinitis pigmentosa. Ophthalmol Sci. 4:1003752024. View Article : Google Scholar

Seliniotaki AK, Ververi A, Koukoula S, Efstathiou G, Gerou S, Ziakas N and Mataftsi A: Female carrier of RPGR mutation presenting with high myopia. Ophthalmic Genet. 45:159–163. 2024. View Article : Google Scholar

Zhang Q, Acland GM, Wu WX, Johnson JL, Pearce-Kelling S, Tulloch B, Vervoort R, Wright AF and Aguirre GD: Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. Hum Mol Genet. 11:993–1003. 2002. View Article : Google Scholar : PubMed/NCBI

Fahim AT, Sullivan LS, Bowne SJ, Jones KD, Wheaton DKH, Khan NW, Heckenlively JR, Jayasundera KT, Branham KH, Andrews CA, et al: X-Chromosome inactivation is a biomarker of clinical severity in female carriers of RPGR-Associated X-Linked retinitis pigmentosa. Ophthalmol Retina. 4:510–520. 2020. View Article : Google Scholar : PubMed/NCBI

Tuekprakhon A, Pawestri AR, Suvannaboon R, Thongyou K, Trinavarat A and Atchaneeyasakul LO: Rare Co-occurrence of visual snow in a female carrier with RPGR(ORF15)-Associated retinal disorder. Front Genet. 12:7280852021. View Article : Google Scholar : PubMed/NCBI

Gocuk SA, Ayton LN, Edwards TL, Jolly JK and Britten-Jones AC: Cone contrast sensitivity testing in X-linked retinal diseases: Insights into genotype, sex and disease severity. Ophthalmic Physiol Opt. 45:2046–2053. 2025. View Article : Google Scholar : PubMed/NCBI

Nassisi M, De Bartolo G, Mohand-Said S, Condroyer C, Antonio A, Lancelot ME, Bujakowska K, Smirnov V, Pugliese T, Neidhardt J, et al: Retrospective natural history study of RPGR-related Cone- and Cone-rod dystrophies while expanding the mutation spectrum of the disease. Int J Mol Sci. 23:71892022. View Article : Google Scholar : PubMed/NCBI

Tran M, Kolesnikova M, Kim AH, Kowal T, Ning K, Mahajan VB, Tsang SH and Sun Y: Clinical characteristics of high myopia in female carriers of pathogenic RPGR mutations: A case series and review of the literature. Ophthalmic Genet. 44:295–303. 2023. View Article : Google Scholar :

Liu C, Sheri N and Benson MD: Inherited retinal diseases with high myopia: A review. Genes (Basel). 16:11832025. View Article : Google Scholar : PubMed/NCBI

Huang L, Lai Y, Sun L, Li S and Ding X: High myopia is common in patients with X-linked retinopathies: Myopic maculopathy analysis. Retina. 44:117–126. 2024. View Article : Google Scholar

Branham K, Andrews CA, Milentijevic D, Narayanan D and Jayasundera KT: Early symptoms in RPGR-associated retinal degeneration: Can we shorten time to diagnosis in the gene therapy era? Ophthalmic Genet. 46:569–575. 2025. View Article : Google Scholar : PubMed/NCBI

Wongchaisuwat N, Amato A, Lamborn AE, Yang P, Everett L and Pennesi ME: Retinitis pigmentosa GTPase regulator-related retinopathy and gene therapy. Saudi J Ophthalmol. 37:276–286. 2023. View Article : Google Scholar :

Meindl A, Dry K, Herrmann K, Manson F, Ciccodicola A, Edgar A, Carvalho MR, Achatz H, Hellebrand H, Lennon A, et al: A gene (RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3). Nat Genet. 13:35–42. 1996. View Article : Google Scholar : PubMed/NCBI

Zou X, Fang S, Wu S, Li H, Sun Z, Zhu T, Wei X and Sui R: Detailed comparison of phenotype between male patients carrying variants in exons 1-14 and ORF15 of RPGR. Exp Eye Res. 198:1081472020. View Article : Google Scholar : PubMed/NCBI

Vervoort R, Lennon A, Bird AC, Tulloch B, Axton R, Miano MG, Meindl A, Meitinger T, Ciccodicola A and Wright AF: Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat Genet. 25:462–466. 2000. View Article : Google Scholar : PubMed/NCBI

Pusch CM, Broghammer M, Jurklies B, Besch D and Jacobi FK: Ten novel ORF15 mutations confirm mutational hot spot in the RPGR gene in European patients with X-linked retinitis pigmentosa. Hum Mutat. 20:4052002. View Article : Google Scholar : PubMed/NCBI

Buraczynska M, Wu W, Fujita R, Buraczynska K, Phelps E, Andréasson S, Bennett J, Birch DG, Fishman GA, Hoffman DR, et al: Spectrum of mutations in the RPGR gene that are identified in 20% of families with X-linked retinitis pigmentosa. Am J Hum Genet. 61:1287–1292. 1997. View Article : Google Scholar : PubMed/NCBI

Xu Z, Lei Y, Qin H, Zhang S, Li P and Yao K: Sigma-1 receptor in retina: Neuroprotective effects and potential mechanisms. Int J Mol Sci. 23:75722022. View Article : Google Scholar : PubMed/NCBI

Wang J, Feng S, Zhang Q, Qin H, Xu C, Fu X, Yan L, Zhao Y and Yao K: Roles of histone acetyltransferases and deacetylases in the retinal development and diseases. Mol Neurobiol. 60:2330–2354. 2023. View Article : Google Scholar : PubMed/NCBI

Zhao Y, Sun B, Fu X, Zuo Z, Qin H and Yao K: YAP in development and disease: Navigating the regulatory landscape from retina to brain. Biomed Pharmacother. 175:1167032024. View Article : Google Scholar : PubMed/NCBI

Zhang S, Xu W, Liu S, Xu F, Chen X, Qin H and Yao K: Anesthetic effects on electrophysiological responses across the visual pathway. Sci Rep. 14:278252024. View Article : Google Scholar : PubMed/NCBI

Yang Z, Yan L, Zhang W, Qi J, An W and Yao K: Dyschromatopsia: A comprehensive analysis of mechanisms and cutting-edge treatments for color vision deficiency. Front Neurosci. 18:12656302024. View Article : Google Scholar : PubMed/NCBI

Wang Z, Zhang Y, Xu C, Peng A, Qin H and Yao K: Advancements in age-related macular degeneration treatment: From traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnology. Biochem Pharmacol. 236:1169022025. View Article : Google Scholar : PubMed/NCBI

Khanna H: More than meets the eye: Current understanding of RPGR function. Adv Exp Med Biol. 1074:521–538. 2018. View Article : Google Scholar : PubMed/NCBI

Yan D, Swain PK, Breuer D, Tucker RM, Wu W, Fujita R, Rehemtulla A, Burke D and Swaroop A: Biochemical characterization and subcellular localization of the mouse retinitis pigmentosa GTPase regulator (mRpgr). J Biol Chem. 273:19656–19663. 1998. View Article : Google Scholar : PubMed/NCBI

Hong DH, Pawlyk BS, Shang J, Sandberg MA, Berson EL and Li T: A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). Proc Natl Acad Sci USA. 97:3649–3654. 2000. View Article : Google Scholar : PubMed/NCBI

Hong DH, Yue G, Adamian M and Li T: Retinitis pigmentosa GTPase regulator (RPGRr)-interacting protein is stably associated with the photoreceptor ciliary axoneme and anchors RPGR to the connecting cilium. J Biol Chem. 276:12091–12099. 2001. View Article : Google Scholar

Megaw RD, Soares DC and Wright AF: RPGR: Its role in photoreceptor physiology, human disease, and future therapies. Exp Eye Res. 138:32–41. 2015. View Article : Google Scholar : PubMed/NCBI

Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A Jr, Woo SJ and Kwon YJ: Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res. 63:107–131. 2018. View Article : Google Scholar

Fahim AT, Bowne SJ, Sullivan LS, Webb KD, Williams JT, Wheaton DK, Birch DG and Daiger SP: Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to RPGR mutations. PLoS One. 6:e230212011. View Article : Google Scholar : PubMed/NCBI

Rao KN, Zhang W, Li L, Ronquillo C, Baehr W and Khanna H: Ciliopathy-associated protein CEP290 modifies the severity of retinal degeneration due to loss of RPGR. Hum Mol Genet. 25:2005–2012. 2016. View Article : Google Scholar : PubMed/NCBI

Linari M, Ueffing M, Manson F, Wright A, Meitinger T and Becker J: The retinitis pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod cyclic GMP phosphodiesterase. Proc Natl Acad Sci USA. 96:1315–1320. 1999. View Article : Google Scholar : PubMed/NCBI

Grayson C, Bartolini F, Chapple JP, Willison KR, Bhamidipati A, Lewis SA, Luthert PJ, Hardcastle AJ, Cowan NJ and Cheetham ME: Localization in the human retina of the X-linked retinitis pigmentosa protein RP2, its homologue cofactor C and the RP2 interacting protein Arl3. Hum Mol Genet. 11:3065–3074. 2002. View Article : Google Scholar : PubMed/NCBI

Wätzlich D, Vetter I, Gotthardt K, Miertzschke M, Chen YX, Wittinghofer A and Ismail S: The interplay between RPGR, PDEδ and Arl2/3 regulate the ciliary targeting of farnesylated cargo. EMBO Rep. 14:465–472. 2013. View Article : Google Scholar

Ying R, Li C, Li H, Zou J, Hu M, Hong Q, Shen Y, Hou L, Cheng H and Zhou R: RPGR is a guanine nucleotide exchange factor for the small GTPase RAB37 required for retinal function via autophagy regulation. Cell Rep. 43:1140102024. View Article : Google Scholar : PubMed/NCBI

Rao KN, Zhang W, Li L, Anand M and Khanna H: Prenylated retinal ciliopathy protein RPGR interacts with PDE6δ and regulates ciliary localization of Joubert syndrome-associated protein INPP5E. Hum Mol Genet. 25:4533–4545. 2016.

Liu X, Han S, Liu F, Yu S, Qin Y, Li J, Jia D, Gao P, Chen X, Tang Z, et al: Retinal degeneration in rpgra mutant zebrafish. Front Cell Dev Biol. 11:11699412023. View Article : Google Scholar : PubMed/NCBI

Murga-Zamalloa CA, Atkins SJ, Peranen J, Swaroop A and Khanna H: Interaction of retinitis pigmentosa GTPase regulator (RPGR) with RAB8A GTPase: Implications for cilia dysfunction and photoreceptor degeneration. Hum Mol Genet. 19:3591–3598. 2010. View Article : Google Scholar : PubMed/NCBI

Lyraki R, Megaw R and Hurd T: Disease mechanisms of X-linked retinitis pigmentosa due to RP2 and RPGR mutations. Biochem Soc Trans. 44:1235–1244. 2016. View Article : Google Scholar : PubMed/NCBI

Baz-Redón N, Sánchez-Bellver L, Fernández-Cancio M, Rovira-Amigo S, Burgoyne T, Ranjit R, Aquino V, Toro-Barrios N, Carmona R, Polverino E, et al: Primary ciliary dyskinesia and retinitis pigmentosa: Novel RPGR variant and possible modifier gene. Cells. 13:5242024. View Article : Google Scholar : PubMed/NCBI

Moore A, Escudier E, Roger G, Tamalet A, Pelosse B, Marlin S, Clément A, Geremek M, Delaisi B, Bridoux AM, et al: RPGR is mutated in patients with a complex X linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa. J Med Genet. 43:326–333. 2006. View Article : Google Scholar

Kolkova Z, Durdik P, Holubekova V, Durdikova A, Jesenak M and Banovcin P: Identification of a novel RPGR mutation associated with retinitis pigmentosa and primary ciliary dyskinesia in a Slovak family: A case report. Front Pediatr. 12:13396642024. View Article : Google Scholar : PubMed/NCBI

Lucas JS, Davis SD, Omran H and Shoemark A: Primary ciliary dyskinesia in the genomics age. Lancet Respir Med. 8:202–216. 2020. View Article : Google Scholar

Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, Nanda A, Davies A, Wood LJ, Salvetti AP, Fischer MD, Aylward JW, Barnard AR, et al: Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 26:354–359. 2020. View Article : Google Scholar : PubMed/NCBI

Cehajic-Kapetanovic J, Martinez-Fernandez de la Camara C, Birtel J, Rehman S, McClements ME, Charbel Issa P, Lotery AJ and MacLaren RE: Impaired glutamylation of RPGR(ORF15) underlies the cone-dominated phenotype associated with truncating distal ORF15 variants. Proc Natl Acad Sci USA. 119:e22087071192022. View Article : Google Scholar : PubMed/NCBI

Pawlyk BS, Bulgakov OV, Sun X, Adamian M, Shu X, Smith AJ, Berson EL, Ali RR, Khani S, Wright AF, et al: Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa. Gene Ther. 23:196–204. 2016. View Article : Google Scholar :

Zhang Q, Giacalone JC, Searby C, Stone EM, Tucker BA and Sheffield VC: Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP. Proc Natl Acad Sci USA. 116:1353–1360. 2019. View Article : Google Scholar : PubMed/NCBI

Hakeem A and Yang S: Regulation of INPP5E in ciliogenesis, development, and disease. Int J Biol Sci. 21:579–594. 2025. View Article : Google Scholar : PubMed/NCBI

Vössing C, Atigbire P, Eilers J, Markus F, Stieger K, Song F and Neidhardt J: The major ciliary isoforms of RPGR build different interaction complexes with INPP5E and RPGRIP1L. Int J Mol Sci. 22:35832021. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Dai H, Wang L, Tao T, Xu J, Sun X, Yang L and Li G: Novel mutations of RPGR in Chinese families with X-linked retinitis pigmentosa. BMC Ophthalmol. 19:2402019. View Article : Google Scholar : PubMed/NCBI

Parmeggiani F, Barbaro V, De Nadai K, Lavezzo E, Toppo S, Chizzolini M, Palù G, Parolin C and Di Iorio E: Identification of novel X-linked gain-of-function RPGR-ORF15 mutation in Italian family with retinitis pigmentosa and pathologic myopia. Sci Rep. 6:391792016. View Article : Google Scholar : PubMed/NCBI

Yokoyama A, Maruiwa F, Hayakawa M, Kanai A, Vervoort R, Wright AF, Yamada K, Niikawa N and Naōi N: Three novel mutations of the RPGR gene exon ORF15 in three Japanese families with X-linked retinitis pigmentosa. Am J Med Genet. 104:232–238. 2001. View Article : Google Scholar : PubMed/NCBI

Andréasson S, Breuer DK, Eksandh L, Ponjavic V, Frennesson C, Hiriyanna S, Filippova E, Yashar BM and Swaroop A: Clinical studies of X-linked retinitis pigmentosa in three Swedish families with newly identified mutations in the RP2 and RPGR-ORF15 genes. Ophthalmic Genet. 24:215–223. 2003. View Article : Google Scholar : PubMed/NCBI

Miano MG, Testa F, Strazzullo M, Trujillo M, De Bernardo C, Grammatico B, Simonelli F, Mangino M, Torrente I, Ruberto G, et al: Mutation analysis of the RPGR gene reveals novel mutations in south European patients with X-linked retinitis pigmentosa. Eur J Hum Genet. 7:687–694. 1999. View Article : Google Scholar : PubMed/NCBI

Hwang S, Jeon S, Yoon JM, Woo SJ, Joo K, Choi YJ, Yoon CK, Kim M, Lee HJ, Byeon SH, et al: RPGR-associated X-linked retinitis pigmentosa: Molecular genetics and clinical characteristics. Am J Ophthalmol. 274:171–183. 2025. View Article : Google Scholar : PubMed/NCBI

Kurata K, Hosono K, Hayashi T, Mizobuchi K, Katagiri S, Miyamichi D, Nishina S, Sato M, Azuma N, Nakano T, et al: X-linked retinitis pigmentosa in Japan: Clinical and genetic findings in male patients and female carriers. Int J Mol Sci. 20:15182019. View Article : Google Scholar : PubMed/NCBI

Thiadens AA, Soerjoesing GG, Florijn RJ, Tjiam AG, den Hollander AI, van den Born LI, Riemslag FC, Bergen AA and Klaver CC: Clinical course of cone dystrophy caused by mutations in the RPGR gene. Graefes Arch Clin Exp Ophthalmol. 249:1527–1535. 2011. View Article : Google Scholar : PubMed/NCBI

Bonetti G, Cozza W, Bernini A, Kaftalli J, Mareso C, Cristofoli F, Medori MC, Colombo L, Martella S, Staurenghi G, et al: Towards a Long-read sequencing approach for the molecular diagnosis of RPGRORF15 genetic variants. Int J Mol Sci. 24:168812023. View Article : Google Scholar :

Daiger SP, Sullivan LS and Bowne SJ: Genes and mutations causing retinitis pigmentosa. Clin Genet. 84:132–141. 2013. View Article : Google Scholar : PubMed/NCBI

Liu HL, Gao FG, Wang DD, Hu FY, Xu P, Chang Q, Xu GZ and Wu JH: Mutation analysis of the RPGR gene in a Chinese cohort. Front Genet. 13:8501222022. View Article : Google Scholar : PubMed/NCBI

Battaglioni S, Benjamin D, Wälchli M, Maier T and Hall MN: mTOR substrate phosphorylation in growth control. Cell. 185:1814–1836. 2022. View Article : Google Scholar : PubMed/NCBI

Liu GY and Sabatini DM: mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 21:183–203. 2020. View Article : Google Scholar : PubMed/NCBI

Marques-Ramos A and Cervantes R: Expression of mTOR in normal and pathological conditions. Mol Cancer. 22:1122023. View Article : Google Scholar : PubMed/NCBI

Venkatesh A, Ma S and Punzo C: TSC but not PTEN loss in starving cones of retinitis pigmentosa mice leads to an autophagy defect and mTORC1 dissociation from the lysosome. Cell Death Dis. 7:e22792016. View Article : Google Scholar : PubMed/NCBI

Song DJ, Bao XL, Fan B and Li GY: Mechanism of cone degeneration in retinitis pigmentosa. Cell Mol Neurobiol. 43:1037–1048. 2023. View Article : Google Scholar

Brown EE, Lewin AS and Ash JD: AMPK may play an important role in the retinal metabolic ecosystem. Adv Exp Med Biol. 1185:477–481. 2019. View Article : Google Scholar

Newton F, Halachev M, Nguyen L, McKie L, Mill P and Megaw R: Autophagy disruption and mitochondrial stress precede photoreceptor necroptosis in multiple mouse models of inherited retinal disorders. Nat Commun. 16:40242025. View Article : Google Scholar : PubMed/NCBI

Xu L, Kong L, Wang J and Ash JD: Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium. Proc Natl Acad Sci USA. 115:10475–10480. 2018. View Article : Google Scholar : PubMed/NCBI

Chen CL, Chen YH, Liang CM, Tai MC, Lu DW and Chen JT: Glucosamine-Induced autophagy through AMPK-mTOR pathway attenuates Lipofuscin-like autofluorescence in human retinal pigment epithelial cells in vitro. Int J Mol Sci. 19:14162018. View Article : Google Scholar

Liu J, Zhang Y, Xu X, Dong X, Pan Y, Sun X and Luo Y: Ginsenoside Ro prevents endothelial injury via promoting Epac1/AMPK-mediated mitochondria protection in early diabetic retinopathy. Pharmacol Res. 211:1075622025. View Article : Google Scholar

Kucharska J, Del Río P, Arango-Gonzalez B, Gorza M, Feuchtinger A, Hauck SM and Ueffing M: Cyr61 activates retinal cells and prolongs photoreceptor survival in rd1 mouse model of retinitis pigmentosa. J Neurochem. 130:227–240. 2014. View Article : Google Scholar : PubMed/NCBI

German OL, Insua MF, Gentili C, Rotstein NP and Politi LE: Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J Neurochem. 98:1507–1520. 2006. View Article : Google Scholar : PubMed/NCBI

Muraleva NA and Kolosova NG: P38 MAPK signaling in the retina: Effects of aging and Age-related macular degeneration. Int J Mol Sci. 24:115862023. View Article : Google Scholar : PubMed/NCBI

Wang L, Tian Y, Li L, Cai M, Zhou X, Su W, Hua X and Yuan X: Temporary alleviation of MAPK by arbutin alleviates oxidative damage in the retina and ARPE-19 cells. Heliyon. 10:e328872024. View Article : Google Scholar : PubMed/NCBI

Maugeri G, Bucolo C, Drago F, Rossi S, Di Rosa M, Imbesi R, D'Agata V and Giunta S: Attenuation of high glucose-induced damage in RPE cells through p38 MAPK signaling pathway inhibition. Front Pharmacol. 12:6846802021. View Article : Google Scholar : PubMed/NCBI

Ding J, Yang N, Yan Y, Wang Y, Wang X, Lu L and Dong K: Rapamycin inhibited photoreceptor necroptosis and protected the retina by activation of autophagy in experimental retinal detachment. Curr Eye Res. 44:739–745. 2019. View Article : Google Scholar : PubMed/NCBI

Saxton RA and Sabatini DM: mTOR signaling in growth, metabolism, and disease. Cell. 168:960–976. 2017. View Article : Google Scholar : PubMed/NCBI

Shen J, Yang X, Dong A, Petters RM, Peng YW, Wong F and Campochiaro PA: Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J Cell Physiol. 203:457–464. 2005. View Article : Google Scholar : PubMed/NCBI

Campochiaro PA and Mir TA: The mechanism of cone cell death in retinitis pigmentosa. Prog Retin Eye Res. 62:24–37. 2018. View Article : Google Scholar

Komeima K, Rogers BS, Lu L and Campochiaro PA: Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci USA. 103:11300–11305. 2006. View Article : Google Scholar : PubMed/NCBI

Piano I, D'Antongiovanni V, Testai L, Calderone V and Gargini C: A nutraceutical strategy to slowing down the progression of cone death in an animal model of retinitis pigmentosa. Front Neurosci. 13:4612019. View Article : Google Scholar : PubMed/NCBI

Venkatesh A, Cheng SY and Punzo C: Loss of the cone-enriched caspase-7 does not affect secondary cone death in retinitis pigmentosa. Mol Vis. 23:944–951. 2017.

Falasconi A, Biagioni M, Novelli E, Piano I, Gargini C and Strettoi E: Retinal phenotype in the rd9 mutant mouse, a model of X-linked RP. Front Neurosci. 13:9912019. View Article : Google Scholar : PubMed/NCBI

Gumerson JD, Alsufyani A, Yu W, Lei J, Sun X, Dong L, Wu Z and Li T: Restoration of RPGR expression in vivo using CRISPR/Cas9 gene editing. Gene Ther. 29:81–93. 2022. View Article : Google Scholar :

Napoli D, Biagioni M, Billeri F, Di Marco B, Orsini N, Novelli E and Strettoi E: Retinal pigment epithelium remodeling in mouse models of retinitis pigmentosa. Int J Mol Sci. 22:53812021. View Article : Google Scholar : PubMed/NCBI

Slijkerman RW, Song F, Astuti GD, Huynen MA, van Wijk E, Stieger K and Collin RW: The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies. Prog Retin Eye Res. 48:137–159. 2015. View Article : Google Scholar : PubMed/NCBI

Zhang X, Shahani U, Reilly J and Shu X: Disease mechanisms and neuroprotection by tauroursodeoxycholic acid in Rpgr knockout mice. J Cell Physiol. 234:18801–18812. 2019. View Article : Google Scholar : PubMed/NCBI

Shu X, Zeng Z, Gautier P, Lennon A, Gakovic M, Patton EE and Wright AF: Zebrafish Rpgr is required for normal retinal development and plays a role in dynein-based retrograde transport processes. Hum Mol Genet. 19:657–670. 2010. View Article : Google Scholar

Tee JJ, Smith AJ, Hardcastle AJ and Michaelides M: RPGR-associated retinopathy: Clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 100:1022–1027. 2016. View Article : Google Scholar : PubMed/NCBI

Mansouri V: X-Linked retinitis pigmentosa gene therapy: Preclinical aspects. Ophthalmol Ther. 12:7–34. 2023. View Article : Google Scholar

Raghupathy RK, McCulloch DL, Akhtar S, Al-mubrad TM and Shu X: Zebrafish model for the genetic basis of X-linked retinitis pigmentosa. Zebrafish. 10:62–69. 2013. View Article : Google Scholar : PubMed/NCBI

Liu F, Chen J, Yu S, Raghupathy RK, Liu X, Qin Y, Li C, Huang M, Liao S, Wang J, et al: Knockout of RP2 decreases GRK1 and rod transducin subunits and leads to photoreceptor degeneration in zebrafish. Hum Mol Genet. 24:4648–4659. 2015. View Article : Google Scholar : PubMed/NCBI

Beltran WA, Cideciyan AV, Lewin AS, Iwabe S, Khanna H, Sumaroka A, Chiodo VA, Fajardo DS, Román AJ, Deng WT, et al: Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA. 109:2132–2137. 2012. View Article : Google Scholar : PubMed/NCBI

Song C, Dufour VL, Cideciyan AV, Ye GJ, Swider M, Newmark JA, Timmers AM, Robinson PM, Knop DR, Chulay JD, et al: Dose range finding studies with two RPGR transgenes in a Canine model of X-Linked retinitis pigmentosa treated with subretinal gene therapy. Hum Gene Ther. 31:743–755. 2020. View Article : Google Scholar : PubMed/NCBI

Huckenpahler AL, Carroll J, Salmon AE, Sajdak BS, Mastey RR, Allen KP, Kaplan HJ and McCall MA: Noninvasive imaging and correlative histology of cone photoreceptor structure in the pig retina = Dose range finding studies with two RPGR transgenes in a Canine model of X-Linked retinitis pigmentosa treated with subretinal gene therapy. Transl Vis Sci Technol. 8:382019. View Article : Google Scholar : PubMed/NCBI

Mussolino C, della Corte M, Rossi S, Viola F, Di Vicino U, Marrocco E, Neglia S, Doria M, Testa F, Giovannoni R, et al: AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther. 18:637–645. 2011. View Article : Google Scholar : PubMed/NCBI

Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD, Wolfe R, Visel M, Stone D, Libby RT, et al: Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci. 52:2775–2783. 2011. View Article : Google Scholar : PubMed/NCBI

Dacey DM: Primate retina: Cell types, circuits and color opponency. Prog Retin Eye Res. 18:737–763. 1999. View Article : Google Scholar : PubMed/NCBI

Fujii R, Matsushita M, Itani Y, Hama A, Natsume T and Takamatsu H: Intravitreal administration of avacincaptad pegol in a nonhuman primate model of Dry Age-related macular degeneration. Pharmacol Res Perspect. 13:e700522025. View Article : Google Scholar

Jia X, Yu Z, Wu J, Hou S, Du Y, Zhu Y, Li Z, Tu S, Zhao L, Su W, et al: Discovery of clinical manifestations in spontaneous glaucoma suspect nonhuman primates. Ophthalmic Res. 66:1406–1416. 2023. View Article : Google Scholar : PubMed/NCBI

Ardon M, Nguyen L, Chen R, Rogers J, Stout T, Thomasy S and Moshiri A: Onset and progression of disease in nonhuman primates with PDE6C cone disorder. Invest Ophthalmol Vis Sci. 65:162024. View Article : Google Scholar : PubMed/NCBI

Bremmer F: Multisensory space: From eye-movements to self-motion. J Physiol. 589:815–823. 2011. View Article : Google Scholar :

Dominik Fischer M, Zobor D, Keliris GA, Shao Y, Seeliger MW, Haverkamp S, Jägle H, Logothetis NK and Smirnakis SM: Detailed functional and structural characterization of a macular lesion in a rhesus macaque. Doc Ophthalmol. 125:179–194. 2012. View Article : Google Scholar : PubMed/NCBI

Mukherjee PK, Marcheselli VL, Serhan CN and Bazan NG: Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA. 101:8491–8496. 2004. View Article : Google Scholar : PubMed/NCBI

Bazan NG: Neuroprotectin D1 (NPD1): A DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 15:159–166. 2005. View Article : Google Scholar : PubMed/NCBI

Jain N, Maguire MG, Flaxel CJ, Kim SJ, Patel S, Smith JR, Weng CY, Kim LA and Yeh S: Dietary supplementation for retinitis pigmentosa: A report by the american academy of ophthalmology. Ophthalmology. 132:354–367. 2025. View Article : Google Scholar

Mukherjee PK, Marcheselli VL, Barreiro S, Hu J, Bok D and Bazan NG: Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling. Proc Natl Acad Sci USA. 104:13152–13157. 2007. View Article : Google Scholar : PubMed/NCBI

Zhong M, Kawaguchi R, Kassai M and Sun H: Retina, retinol, retinal and the natural history of vitamin A as a light sensor. Nutrients. 4:2069–2096. 2012. View Article : Google Scholar

Hughbanks-Wheaton DK, Birch DG, Fish GE, Spencer R, Pearson NS, Takacs A and Hoffman DR: Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: The 4-year DHAX trial. Invest Ophthalmol Vis Sci. 55:4958–4966. 2014. View Article : Google Scholar : PubMed/NCBI

Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, Fish GE, Spencer R, Takacs A, Klein M, Locke KG and Birch DG: Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): A randomized clinical trial. JAMA Ophthalmol. 132:866–873. 2014. View Article : Google Scholar : PubMed/NCBI

Lin JB, Murakami Y, Miller JW and Vavvas DG: Neuroprotection for Age-related macular degeneration. Ophthalmol Sci. 2:1001922022. View Article : Google Scholar : PubMed/NCBI

Fudalej E, Justyniarska M, Kasarełło K, Dziedziak J, Szaflik JP and Cudnoch-Jędrzejewska A: Neuroprotective factors of the retina and their role in promoting survival of retinal ganglion cells: A review. Ophthalmic Res. 64:345–355. 2021. View Article : Google Scholar : PubMed/NCBI

Ou K, Li Y, Liu L, Li H, Cox K, Wu J, Liu J and Dick AD: Recent developments of neuroprotective agents for degenerative retinal disorders. Neural Regen Res. 17:1919–1928. 2022. View Article : Google Scholar : PubMed/NCBI

Huang K, Deng H, Wang S, Zhang F, Huang G, Wang L, Liu J, Zhao X, Ren H, Yang G, et al: Melanin-like nanomedicine functions as a novel RPE ferroptosis inhibitor to ameliorate retinal degeneration and visual impairment in Dry Age-related macular degeneration. Adv Healthc Mater. 13:e24016132024. View Article : Google Scholar : PubMed/NCBI

Wang J, Zhao J, Cui X, Mysona BA, Navneet S, Saul A, Ahuja M, Lambert N, Gazaryan IG, Thomas B, et al: The molecular chaperone sigma 1 receptor mediates rescue of retinal cone photoreceptor cells via modulation of NRF2. Free Radic Biol Med. 134:604–616. 2019. View Article : Google Scholar : PubMed/NCBI

Zou M, Ke Q, Nie Q, Qi R, Zhu X, Liu W, Hu X, Sun Q, Fu JL, Tang X, et al: Inhibition of cGAS-STING by JQ1 alleviates oxidative stress-induced retina inflammation and degeneration. Cell Death Differ. 29:1816–1833. 2022. View Article : Google Scholar : PubMed/NCBI

Zhu X, Liu W, Tang X, Chen Y, Ge X, Ke Q, Liang X, Gan Y, Zheng Y, Zou M, et al: The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage. J Neuroinflammation. 20:1192023. View Article : Google Scholar : PubMed/NCBI

Qin H, Xu W and Yao K: CRISPR-based genome editing in disease treatment. Trends Mol Med. 29:673–674. 2023. View Article : Google Scholar : PubMed/NCBI

Dasgupta I, Flotte TR and Keeler AM: CRISPR/Cas-dependent and Nuclease-free in vivo therapeutic gene editing. Hum Gene Ther. 32:275–293. 2021. View Article : Google Scholar : PubMed/NCBI

Pulman J, Sahel JA and Dalkara D: New editing tools for gene therapy in inherited retinal dystrophies. Crispr J. 5:377–388. 2022. View Article : Google Scholar : PubMed/NCBI

Xu F, Zheng C, Xu W, Zhang S, Liu S, Chen X and Yao K: Breaking genetic shackles: The advance of base editing in genetic disorder treatment. Front Pharmacol. 15:13641352024. View Article : Google Scholar : PubMed/NCBI

Fu X, Feng S, Qin H, Yan L, Zheng C and Yao K: Microglia: The breakthrough to treat neovascularization and repair blood-retinal barrier in retinopathy. Front Mol Neurosci. 16:11002542023. View Article : Google Scholar : PubMed/NCBI

Campa C, Gallenga CE, Bolletta E and Perri P: The role of gene therapy in the treatment of retinal diseases: A review. Curr Gene Ther. 17:194–213. 2017. View Article : Google Scholar : PubMed/NCBI

Xu W, Zhang S, Qin H and Yao K: From bench to bedside: Cutting-edge applications of base editing and prime editing in precision medicine. J Transl Med. 22:11332024. View Article : Google Scholar : PubMed/NCBI

Xia X and Guo X: Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies. Front Med (Lausanne). 10:13100502023. View Article : Google Scholar : PubMed/NCBI

Lykken EA, Shyng C, Edwards RJ, Rozenberg A and Gray SJ: Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 10:162018. View Article : Google Scholar : PubMed/NCBI

Wiley LA, Boyce TM, Meyering EE, Ochoa D, Sheehan KM, Stone EM, Mullins RF, Tucker BA and Han IC: The degree of Adeno-Associated Virus-induced retinal inflammation varies based on serotype and route of delivery: Intravitreal, subretinal, or suprachoroidal. Hum Gene Ther. 34:530–539. 2023. View Article : Google Scholar : PubMed/NCBI

Puertas-Neyra K, Usategui-Martín R, Coco RM and Fernandez-Bueno I: Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases. Neural Regen Res. 15:1631–1638. 2020. View Article : Google Scholar : PubMed/NCBI

Giacalone JC, Andorf JL, Zhang Q, Burnight ER, Ochoa D, Reutzel AJ, Collins MM, Sheffield VC, Mullins RF, Han IC, et al: Development of a molecularly stable gene therapy vector for the treatment of RPGR-Associated X-Linked retinitis pigmentosa. Hum Gene Ther. 30:967–974. 2019. View Article : Google Scholar : PubMed/NCBI

Hong DH, Pawlyk BS, Adamian M, Sandberg MA and Li T: A single, abbreviated RPGR-ORF15 variant reconstitutes RPGR function in vivo. Invest Ophthalmol Vis Sci. 46:435–441. 2005. View Article : Google Scholar : PubMed/NCBI

Wang JH, Zhan W, Gallagher TL and Gao G: Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review. Mol Ther. 32:4185–4207. 2024. View Article : Google Scholar : PubMed/NCBI

Trapani I, Colella P, Sommella A, Iodice C, Cesi G, de Simone S, Marrocco E, Rossi S, Giunti M, Palfi A, et al: Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. 6:194–211. 2014. View Article : Google Scholar :

Ford JL, Karatza E, Mody H, Nagaraja Shastri P, Khajeh Pour S, Yang TY, Swanson M, Chao D and Devineni D: Clinical pharmacology perspective on development of Adeno-associated virus Vector-based retina gene therapy. Clin Pharmacol Ther. 115:1212–1232. 2024. View Article : Google Scholar : PubMed/NCBI

Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, et al: Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 29:464–488. 2021. View Article : Google Scholar

Alsalloum A, Gornostal E, Mingaleva N, Pavlov R, Kuznetsova E, Antonova E, Nadzhafova A, Kolotova D, Kadyshev V, Mityaeva O, et al: A Comparative analysis of models for AAV-Mediated gene therapy for inherited retinal diseases. Cells. 13:17062024. View Article : Google Scholar : PubMed/NCBI

Naldini L: Gene therapy returns to centre stage. Nature. 526:351–360. 2015. View Article : Google Scholar : PubMed/NCBI

Fuller-Carter PI, Basiri H, Harvey AR and Carvalho LS: Focused update on AAV-Based gene therapy clinical trials for inherited retinal degeneration. BioDrugs. 34:763–781. 2020. View Article : Google Scholar : PubMed/NCBI

Narfström K, Katz ML, Bragadottir R, Seeliger M, Boulanger A, Redmond TM, Caro L, Lai CM and Rakoczy PE: Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci. 44:1663–1672. 2003. View Article : Google Scholar : PubMed/NCBI

Smith AJ, Schlichtenbrede FC, Tschernutter M, Bainbridge JW, Thrasher AJ and Ali RR: AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther. 8:188–195. 2003. View Article : Google Scholar : PubMed/NCBI

Kansara V, Muya L, Wan CR and Ciulla TA: Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases. J Ocul Pharmacol Ther. 36:384–392. 2020. View Article : Google Scholar : PubMed/NCBI

Biber J, Gandor C, Becirovic E and Michalakis S: Retina-directed gene therapy: Achievements and remaining challenges. Pharmacol Ther. 271:1088622025. View Article : Google Scholar : PubMed/NCBI

McDonald A and Wijnholds J: Retinal ciliopathies and potential gene therapies: A focus on human iPSC-derived organoid models. Int J Mol Sci. 25:28872024. View Article : Google Scholar : PubMed/NCBI

Pavlou M, Schön C, Occelli LM, Rossi A, Meumann N, Boyd RF, Bartoe JT, Siedlecki J, Gerhardt MJ, Babutzka S, et al: Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. EMBO Mol Med. 13:e133922021. View Article : Google Scholar :

Hu S, Du J, Chen N, Jia R, Zhang J, Liu X and Yang L: In vivo CR ISPR/Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-Linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 61:312020. View Article : Google Scholar

Fu Y, He X, Ma L, Gao XD, Liu P, Shi H, Chai P, Ge S, Jia R, Liu DR, et al: In vivo prime editing rescues photoreceptor degeneration in nonsense mutant retinitis pigmentosa. Nat Commun. 16:23942025. View Article : Google Scholar : PubMed/NCBI

Wu Z, Hiriyanna S, Qian H, Mookherjee S, Campos MM, Gao C, Fariss R, Sieving PA, Li T, Colosi P, et al: A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. Hum Mol Genet. 24:3956–3970. 2015. View Article : Google Scholar : PubMed/NCBI

Chahine Karam F, Loi TH, Ma A, Nash BM, Grigg JR, Parekh D, Riley LG, Farnsworth E, Bennetts B, Gonzalez-Cordero A, et al: Human iPSC-derived retinal organoids and retinal pigment epithelium for novel intronic RPGR variant assessment for therapy suitability. J Pers Med. 12:5022022. View Article : Google Scholar : PubMed/NCBI

Deng WL, Gao ML, Lei XL, Lv JN, Zhao H, He KW, Xia XX, Li LY, Chen YC, Li YP, et al: Gene correction reverses ciliopathy and photoreceptor loss in iPSC-Derived retinal organoids from retinitis pigmentosa patients. Stem Cell Reports. 10:1267–1281. 2018. View Article : Google Scholar : PubMed/NCBI

Bassuk AG, Zheng A, Li Y, Tsang SH and Mahajan VB: Precision medicine: Genetic repair of retinitis pigmentosa in patient-derived stem cells. Sci Rep. 6:199692016. View Article : Google Scholar : PubMed/NCBI

Li T, Ma Y, Cheng Y, Zhao Y, Qiu Z, Liu H, Zhang D, Wu J, Li J, Zhang S, et al: Single-cell transcriptomic dataset of RPGR-associated retinitis pigmentosa patient-derived retinal organoids. Sci Data. 11:12852024. View Article : Google Scholar : PubMed/NCBI

Lin B, McLelland BT, Aramant RB, Thomas BB, Nistor G, Keirstead HS and Seiler MJ: Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction. Invest Ophthalmol Vis Sci. 61:342020. View Article : Google Scholar : PubMed/NCBI

West EL, Majumder P, Naeem A, Fernando M, O'Hara-Wright M, Lanning E, Kloc M, Ribeiro J, Ovando-Roche P, Shum IO, et al: Antioxidant and lipid supplementation improve the development of photoreceptor outer segments in pluripotent stem cell-derived retinal organoids. Stem Cell Reports. 17:775–788. 2022. View Article : Google Scholar : PubMed/NCBI

Scherbakova I, Ragi SD and Sharma T: Ocular injection techniques for retinitis pigmentosa: Intravitreal, subretinal, and suprachoroidal. Methods Mol Biol. 2560:375–392. 2023. View Article : Google Scholar

Kovacs KD, Ciulla TA and Kiss S: Advancements in ocular gene therapy delivery: Vectors and subretinal, intravitreal, and suprachoroidal techniques. Expert Opin Biol Ther. 22:1193–1208. 2022. View Article : Google Scholar : PubMed/NCBI

Mackenbrock LHB, Auffarth GU, Albrecht M, Naujokaitis T, Kessler LJ, Mayer CS and Khoramnia R: Anterior segment complications following intravitreal injection. Klin Monbl Augenheilkd. 241:917–922. 2024. View Article : Google Scholar : PubMed/NCBI

Zhao CS, Chwialkowski K, Wai KM, Mruthyunjaya P, Rahimy E and Koo EB: Risk of cataract surgery complications in patients with prior intravitreal injection therapy. Am J Ophthalmol. 272:106–116. 2025. View Article : Google Scholar : PubMed/NCBI

Prado DA, Acosta-Acero M and Maldonado RS: Gene therapy beyond luxturna: A new horizon of the treatment for inherited retinal disease. Curr Opin Ophthalmol. 31:147–154. 2020. View Article : Google Scholar : PubMed/NCBI

Takahashi K, Morizane Y, Hisatomi T, Tachibana T, Kimura S, Hosokawa MM, Shiode Y, Hirano M, Doi S, Toshima S, et al: The influence of subretinal injection pressure on the microstructure of the monkey retina. PLoS One. 13:e02099962018. View Article : Google Scholar

Dufour VL, Cideciyan AV, Ye GJ, Song C, Timmers A, Habecker PL, Pan W, Weinstein NM, Swider M, Durham AC, et al: Toxicity and efficacy evaluation of an Adeno-associated virus vector expressing Codon-optimized RPGR delivered by subretinal injection in a Canine model of X-linked retinitis pigmentosa. Hum Gene Ther. 31:253–267. 2020. View Article : Google Scholar : PubMed/NCBI

Qi Y, Dai X, Zhang H, He Y, Zhang Y, Han J, Zhu P, Zhang Y, Zheng Q, Li X, et al: Trans-corneal subretinal injection in mice and its effect on the function and morphology of the retina. PLoS One. 10:e01365232015. View Article : Google Scholar : PubMed/NCBI

Peng Y, Tang L and Zhou Y: Subretinal injection: A review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res. 58:217–226. 2017. View Article : Google Scholar : PubMed/NCBI

Tripepi D, Jalil A, Ally N, Buzzi M, Moussa G, Rothschild PR, Rossi T, Ferrara M and Romano MR: The role of subretinal injection in ophthalmic surgery: Therapeutic agent delivery and other indications. Int J Mol Sci. 24:105352023. View Article : Google Scholar : PubMed/NCBI

Wu KY, Fujioka JK, Gholamian T, Zaharia M and Tran SD: Suprachoroidal injection: A novel approach for targeted drug delivery. Pharmaceuticals (Basel). 16:12412023. View Article : Google Scholar : PubMed/NCBI

Rahman S, Tayyab H and Siddiqui MAR: Suprachoroidal triamcinolone acetonide injection to treat macular edema: A Review. J Vitreoretin Dis. 8:699–708. 2024. View Article : Google Scholar : PubMed/NCBI

Han IC, Cheng JL, Burnight ER, Ralston CL, Fick JL, Thomsen GJ, Tovar EF, Russell SR, Sohn EH, Mullins RF, et al: Retinal tropism and transduction of Adeno-Associated virus varies by serotype and route of delivery (Intravitreal, Subretinal, or Suprachoroidal) in rats. Hum Gene Ther. 31:1288–1299. 2020. View Article : Google Scholar : PubMed/NCBI

Wu KY, Gao A, Giunta M and Tran SD: What's new in ocular drug delivery: Advances in suprachoroidal injection since 2023. Pharmaceuticals (Basel). 17:10072024. View Article : Google Scholar : PubMed/NCBI

Jung JH, Chiang B, Grossniklaus HE and Prausnitz MR: Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle. J Control Release. 277:14–22. 2018. View Article : Google Scholar : PubMed/NCBI

Gagnon NA, Hartley C and Gilger BC: Efficacy and safety of suprachoroidal triamcinolone injection in horses with poorly responsive equine recurrent uveitis. Vet Ophthalmol. 24:308–312. 2021. View Article : Google Scholar : PubMed/NCBI

Lee H and Lotery A: Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3. Lancet. 390:823–824. 2017. View Article : Google Scholar : PubMed/NCBI

Zu H and Gao D: Non-viral vectors in gene therapy: Recent development, challenges, and prospects. AAPS J. 23:782021. View Article : Google Scholar : PubMed/NCBI

Wang C, Pan C, Yong H, Wang F, Bo T, Zhao Y, Ma B, He W and Li M: Emerging non-viral vectors for gene delivery. J Nanobiotechnology. 21:2722023. View Article : Google Scholar : PubMed/NCBI

Ren S, Wang M, Wang C, Wang Y, Sun C, Zeng Z, Cui H and Zhao X: Application of Non-viral vectors in drug delivery and gene therapy. Polymers (Basel). 13:33072021. View Article : Google Scholar : PubMed/NCBI

Chapa González C, Martínez Saráoz JV, Roacho Pérez JA and Olivas Armendáriz I: Lipid nanoparticles for gene therapy in ocular diseases. Daru. 31:75–82. 2023. View Article : Google Scholar : PubMed/NCBI

Carvalho C, Lemos L, Antas P and Seabra MC: Gene therapy for inherited retinal diseases: Exploiting new tools in genome editing and nanotechnology. Front Ophthalmol (Lausanne). 3:12705612023. View Article : Google Scholar

Schnichels S, Simmang D, Löscher M, Herrmann A, de Vries JW, Spitzer MS and Hurst J: Lipid-DNA nanoparticles as Drug-delivery vehicles for the treatment of retinal diseases. Pharmaceutics. 15:5322023. View Article : Google Scholar : PubMed/NCBI

Baig MS, Karade SK, Ahmad A, Khan MA, Haque A, Webster TJ, Faiyazuddin M and Al-Qahtani NH: Lipid-based nanoparticles: Innovations in ocular drug delivery. Front Mol Biosci. 11:14219592024. View Article : Google Scholar : PubMed/NCBI

Gugleva V and Andonova V: Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms. Pharmaceuticals (Basel). 16:4742023. View Article : Google Scholar : PubMed/NCBI

Lam BL, Scholl HPN, Doub D, Sperling M, Hashim M and Li N: A systematic literature review of disease progression reported in RPGR-associated X-linked retinitis pigmentosa. Retina. 44:1–9. 2024. View Article : Google Scholar

Zada M, Cornish EE, Fraser CL, Jamieson RV and Grigg JR: Natural history and clinical biomarkers of progression in X-linked retinitis pigmentosa: A systematic review. Acta Ophthalmol. 99:499–510. 2021. View Article : Google Scholar

Christou EE, Josan AS, Cehajic-Kapetanovic J and MacLaren RE: Establishing clinical trial endpoints in selecting patients for RPGR retinal gene therapy. Transl Vis Sci Technol. 13:182024. View Article : Google Scholar : PubMed/NCBI

Birch DG, Locke KG, Felius J, Klein M, Wheaton DK, Hoffman DR and Hood DC: Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa. Ophthalmology. 122:833–839. 2015. View Article : Google Scholar : PubMed/NCBI

Stephenson KAJ, Tse T, Hwang J, Kavetskyi A, Dhanji SR, Kolawole OU, Gregory-Evans CY, Pakzad-Vaezi K, Mammo ZN, Gregory-Evans K, et al: Quantitative choroidal analysis of molecularly characterized retinitis pigmentosa. Invest Ophthalmol Vis Sci. 66:112025. View Article : Google Scholar : PubMed/NCBI

Iftikhar M, Lemus M, Usmani B, Campochiaro PA, Sahel JA, Scholl HPN and Shah SMA: Classification of disease severity in retinitis pigmentosa. Br J Ophthalmol. 103:1595–1599. 2019. View Article : Google Scholar : PubMed/NCBI

De Silva SR, Arno G, Robson AG, Fakin A, Pontikos N, Mohamed MD, Bird AC, Moore AT, Michaelides M, Webster AR, et al: The X-linked retinopathies: Physiological insights, pathogenic mechanisms, phenotypic features and novel therapies. Prog Retin Eye Res. 82:1008982021. View Article : Google Scholar

Ghoraba HH, Akhavanrezayat A, Karaca I, Yavari N, Lajevardi S, Hwang J, Regenold J, Matsumiya W, Pham B, Zaidi M, et al: Ocular gene therapy: A Literature review with special focus on immune and inflammatory responses. Clin Ophthalmol. 16:1753–1771. 2022. View Article : Google Scholar : PubMed/NCBI

Hugi F, Vollmer J, Renaud L and Machacek M: A Semimechanistic ocular pharmacokinetic model for ADVM-022 gene therapy describing the Dose-exposure relationship in monkeys and the scaling to human. Mol Pharm. 22:4612–4623. 2025. View Article : Google Scholar : PubMed/NCBI

Martinez-Fernandez de la Camara C, Cehajic-Kapetanovic J and MacLaren RE: Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa. Expert Opin Emerg Drugs. 27:431–443. 2022. View Article : Google Scholar : PubMed/NCBI

Yang P, Birch D, Lauer A, Sisk R, Anand R, Pennesi ME, Iannaccone A, Yaghy A, Scaria A, Jung JA, et al: Subretinal gene therapy drug AGTC-501 for XLRP Phase 1/2 multicenter study (HORIZON): 24-month safety and efficacy results. Am J Ophthalmol. 271:268–285. 2025. View Article : Google Scholar

Michaelides M, Besirli CG, Yang Y, DE Guimaraes TAC, Wong SC, Huckfeldt RM, Comander JI, Sahel JA, Shah SM, Tee JJL, et al: Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) gene therapy: Safety and efficacy in RPGR-associated X-linked retinitis pigmentosa. Am J Ophthalmol. 267:122–134. 2024. View Article : Google Scholar : PubMed/NCBI

Ren D, Fisson S, Dalkara D and Ail D: Immune responses to gene editing by viral and Non-viral delivery vectors used in retinal gene therapy. Pharmaceutics. 14:19732022. View Article : Google Scholar : PubMed/NCBI

Casey GA, Papp KM and MacDonald IM: Ocular gene therapy with Adeno-associated virus vectors: Current outlook for patients and researchers. J Ophthalmic Vis Res. 15:396–399. 2020. View Article : Google Scholar : PubMed/NCBI

Butterfield GL, Reisman SJ, Iglesias N and Gersbach CA: Gene regulation technologies for gene and cell therapy. Mol Ther. 33:2104–2122. 2025. View Article : Google Scholar : PubMed/NCBI

Beltran WA, Cideciyan AV, Iwabe S, Swider M, Kosyk MS, McDaid K, Martynyuk I, Ying GS, Shaffer J, Deng WT, et al: Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proc Natl Acad Sci USA. 112:E5844–E5853. 2015. View Article : Google Scholar : PubMed/NCBI

Beltran WA, Cideciyan AV, Boye SE, Ye GJ, Iwabe S, Dufour VL, Marinho LF, Swider M, Kosyk MS, Sha J, et al: Optimization of retinal gene therapy for X-Linked retinitis pigmentosa due to RPGR mutations. Mol Ther. 25:1866–1880. 2017. View Article : Google Scholar : PubMed/NCBI

Ren M, Chen X, Gao P, Huang Y, Yu S, Reilly J, Sun K, Han Y, Hu H, Li P, et al: RPGRORF15 mutations disrupt lysosomal lipid metabolism in retinal pigment epithelium cells and cause retinitis pigmentosa. Invest Ophthalmol Vis Sci. 66:612025. View Article : Google Scholar : PubMed/NCBI

Far BF, Akbari M, Habibi MA, Katavand M and Nasseri S: CRISPR technology in disease management: An updated review of clinical translation and therapeutic potential. Cell Prolif. 58:e700992025. View Article : Google Scholar : PubMed/NCBI

von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, Lotery AJ, Jalil A, Lam BL and MacLaren RE; XIRIUS Part 1 Study GroupXOLARIS Study Group: Changes in retinal sensitivity associated with cotoretigene toliparvovec in X-Linked retinitis pigmentosa with RPGR gene variations. JAMA Ophthalmol. 141:275–283. 2023. View Article : Google Scholar : PubMed/NCBI

Ling S, Zhang X, Dai Y, Jiang Z, Zhou X, Lu S, Qian X, Liu J, Selfjord N, Satir TM, et al: Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy. Nat Nanotechnol. 20:543–553. 2025. View Article : Google Scholar : PubMed/NCBI

Banou L, Sarrafpour S, Teng CC and Liu J: Ocular gene therapy: An overview of viral vectors, immune responses, and future directions. Yale J Biol Med. 97:491–503. 2024. View Article : Google Scholar : PubMed/NCBI

Jony MJ, Joshi A, Dash A and Shukla S: Non-Viral delivery systems to transport nucleic acids for inherited retinal disorders. Pharmaceuticals (Basel). 18:872025. View Article : Google Scholar : PubMed/NCBI

Lim Y, Campochiaro PA and Green JJ: Suprachoroidal delivery of viral and nonviral vectors for treatment of retinal and choroidal vascular diseases. Am J Ophthalmol. 277:518–533. 2025. View Article : Google Scholar

Wu H, Dong L, Jin S, Zhao Y and Zhu L: Innovative gene delivery systems for retinal disease therapy. Neural Regen Res. 21:542–552. 2026. View Article : Google Scholar

Sultana S, Yusuf M and Sharma V: Nanovesicular drug delivery systems for rare ocular diseases: Advances, challenges, and future directions. AAPS PharmSciTech. 26:1972025. View Article : Google Scholar : PubMed/NCBI

Adewale OB, Davids H, Cairncross L and Roux S: Toxicological behavior of gold nanoparticles on various models: Influence of physicochemical properties and other factors. Int J Toxicol. 38:357–384. 2019. View Article : Google Scholar : PubMed/NCBI

Chis AA, Dobrea CM, Rus LL, Frum A, Morgovan C, Butuca A, Totan M, Juncan AM, Gligor FG and Arseniu AM: Dendrimers as Non-viral vectors in gene-directed enzyme prodrug therapy. Molecules. 26:59762021. View Article : Google Scholar : PubMed/NCBI

Galluzzi F, Francia S, Cupini S, Gianiorio T, Mantero G, DiFrancesco ML, Ravasenga T, Jasnoor, Attanasio M, Maya-Vetencourt JF, et al: Graphene oxide increases the phototransduction efficiency of copolymeric nanoimplants and rescues visual functions in rat and pig models of Retinitis pigmentosa. Nat Commun. 16:87212025. View Article : Google Scholar : PubMed/NCBI

Szabó V, Varsányi B, Barboni M, Takács Á, Knézy K, Molnár MJ, Nagy ZZ, György B and Rivolta C: Insights into eye genetics and recent advances in ocular gene therapy. Mol Cell Probes. 79:1020082025. View Article : Google Scholar : PubMed/NCBI